TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

TRACON Pharmaceuticals reports positive interim data, focuses on growth strategies

TRACON Pharmaceuticals showcased promising interim data from the ENVASARC trial, reflecting positive efficacy of ENVA treatment and strategic advancements in product development.
While facing challenges such as financial losses and regulatory compliance, TRACON's focus on cost-saving measures and operational efficiency positions it for sustainable growth.
The company's strong cash position, commitment to advancing its pipeline, and opportunities for collaboration and portfolio expansion signal a promising outlook for future growth and innovation.
By leveraging its product development platform and upcoming trial data releases, TRACON aims to drive value creation, financial stability, and regulatory compliance in the competitive pharmaceutical landscape.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TRACON Pharmaceuticals Inc (NASDAQ:TCON) says the Independent Data Monitoring Committee for the ENVASARC pivotal trial has recommended that the trial will proceed as planned following the review of safety data from more than 20 patients enrolled so far.  The company said the safety data reviewed included data from more than 10 patients enrolled into cohort A of treatment with single-agent envafolimab and more than 10 patients enrolled into cohort B of treatment with envafolimab and Yervoy (ipilimumab) for sarcoma, a rare group of cancers that arise in the bones and connective tissue.

TRACON Pharmaceuticals says ENVASARC trial to proceed as planned after Independent Data Monitoring Committee recommendation

SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the Jefferies Virtual Healthcare Conference on June 4, 2021 at 2:30pm Eastern Time.

TRACON Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

SAN DIEGO, May 20, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced the presentation of two abstracts at the upcoming American Society of Clinical Oncology (ASCO) 2021 annual meeting, being held virtually June 4-8, 2021.

TRACON Pharmaceuticals Announces Poster Presentations at the 2021 ASCO Virtual Annual Meeting

TRACON Pharmaceuticals (TCON) CEO Charles Theuer on Q1 2021 Results - Earnings Call Transcript

TRACON Pharmaceuticals Inc (NASDAQ:TCON) ended the first quarter of 2021 on March 31 with cash and equivalents of $30.4 million, which it said will fund its operations into the second half of 2022. The company also noted that as of May 5, it has initiated 22 US clinical sites and enrolled more than 20 patients in the pivotal ENVASARC trial of single-agent envafolimab and envafolimab combined with Yervoy, which has triggered the initial Data Monitoring Committee review of safety data from each cohort.

TRACON Pharmaceuticals ends 1Q with $30.4M to fund its cancer drug trials

SAN DIEGO, May 05, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced financial results for the first quarter ended March 31, 2021. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time.

TRACON Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

SAN DIEGO, May 03, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today the appointment of Dongliang Zhuang, Ph.D. as Vice President of Statistics and Biometrics.

TRACON Pharmaceuticals Announces Appointment of Dongliang Zhuang, Ph.D. as Vice President of Statistics and Biometrics

SAN DIEGO, April 28, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it will report its first quarter 2021 financial and operating results after the close of U.S. financial markets on Wednesday, May 5, 2021. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.

TRACON to Report First Quarter 2021 Financial Results and Company Highlights on May 5, 2021

NEW YORK, April 26, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of TRACON Pharmaceuticals, Inc. (NASDAQ: TCON). If you are a shareholder of TRACON Pharmaceuticals, Inc. and are interested in obtaining additional information regarding this investigation, free of charge, please visit us at: http://pjlfirm.com/tracon-pharmaceuticals-inc/ You may also contact Robert H.

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating TRACON Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

Poster to Highlight ENVASARC Pivotal Trial Evaluating Envafolimab in Sarcoma Poster to Highlight ENVASARC Pivotal Trial Evaluating Envafolimab in Sarcoma

TRACON Pharmaceuticals Announces Poster Presentation at the 2021 AACR Virtual Annual Meeting

SAN DIEGO, March 09, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021 at 3:10pm Eastern Time.

TRACON Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference

TRACON Pharmaceuticals Inc (NASDAQ:TCON) said it has appointed Dr Lisa Johnson-Pratt to the company's board of directors. TRACON noted that Dr Johnson-Pratt brings more than two decades of broad business and commercialization leadership experience to the company and she currently serves as the senior vice president, New Product Planning at Ionis Pharmaceuticals, Inc. “We are very pleased to welcome Lisa to TRACON's Board of Directors.

TRACON Pharmaceuticals appoints pharma executive Dr Lisa Johnson-Pratt to its board of directors

SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today the appointment of Lisa Johnson-Pratt, M.D., Senior Vice President, New Product Planning at Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), to its Board of Directors.

TRACON Pharmaceuticals Announces Appointment of Lisa Johnson-Pratt, M.D., to its Board of Directors

SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference, being held virtually March 9-10, 2021.

TRACON Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference

TRACON Pharmaceuticals, Inc. (TCON) CEO Charles Theuer on Q4 2020 Results - Earnings Call Transcript

SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced financial results for the fourth quarter and year ended December 31, 2020. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time.

TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update

SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it will report its fourth quarter and full year 2020 financial and operating results after the close of U.S. financial markets on Thursday, February 25, 2021. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.

TRACON to Report Fourth Quarter and Full Year 2020 Financial Results and Company Highlights on February 25, 2021

NDA was Submitted in November by TRACON's Corporate Partners, Alphamab Oncology and 3D Medicines, in the Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer NDA was Submitted in November by TRACON's Corporate Partners, Alphamab Oncology and 3D Medicines, in the Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer

TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China for Priority Review

SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Virtual BioConnect 2021 Conference, being held January 11-14, 2021.

TRACON Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

NDA was Submitted in November in the Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer NDA was Submitted in November in the Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer

TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China that was Submitted by its Corporate Partners Alphamab Oncology and 3D Medicines

SAN DIEGO, Dec. 29, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that it has entered into a securities purchase agreement with an existing investor to sell an aggregate of 520,961 shares of common stock in a registered direct offering at a price of $9.61 per share, which was the closing price of the Company's common stock on December 28, 2020. The aggregate gross proceeds to TRACON from the offering are expected to be $5.0 million. The closing of the offering is expected to occur on or about December 30, 2020.

TRACON Pharmaceuticals Announces $5.0 Million Registered Direct Offering

SAN DIEGO, Dec. 22, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that it has entered into a securities purchase agreement with new and existing investors to sell an aggregate of 1.1 million shares of common stock in a registered direct offering at a price of $8.06 per share, which is the five-day average closing price of the Company's common stock as of December 21, 2020. The aggregate gross proceeds to TRACON from the offering are expected to be $8.8 million. The closing of the offering is expected to occur on or about December 22, 2020.

TRACON Pharmaceuticals Announces $8.8 Million Registered Direct Offering

Company Expects Interim Data in Mid-2021 Company Expects Interim Data in Mid-2021

TRACON Pharmaceuticals Announces Dosing of First Patient in ENVASARC Pivotal Trial

Aerpio Pharmaceuticals Inc

Repligen

Here we discuss three potential stocks that can gain following mass availability of vaccine. Vaccination may release pent-up demand across sectors.

3 Biotech Stocks to Buy on First Vaccine Approval Optimism

SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced the publication of clinical data that provides molecular insight into TRC102's mechanism of action and patient populations most likely to respond to treatment. The article, entitled, “Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment,” highlights the clinical features and tumor biology of an exceptional responder patient treated with TRC102 at the National Cancer Institute (NCI): https://www.traconpharma.com/wp-content/uploads/2020/11/Can_Cell_2020_Nov_Mol_Analysis_ER.pdf

TRACON Announces Publication in Cancer Cell of Clinical Data that Provides Molecular Insight into the Mechanism of Action of TRC102 and Patient Populations Most Likely to Respond to Treatment

News for TRACON Pharmaceuticals Stock (TCON)